Alert: Claims Focus on Alleged Misrepresentations About Setrusumab Efficacy Potential
NEW YORK, March 4, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP reminds purchasers of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) securities of a pending securities class action. Investors have until April 6, 2026 to seek lead plaintiff status.
THE CASE: A class action seeks to recover damages for investors who purchased Ultragenyx securities between August 3, 2023 and December 26, 2025.
YOUR OPTIONS: You may be entitled to compensation without payment of any out-of-pocket fees.
See if you can recover losses or contact Joseph E. Levi, Esq. at jlevi@levikorsinsky.com | (212) 363-7500.
The December 29, 2025 Stock Collapse
From a closing price of $34.19 on December 26, 2025, Ultragenyx shares plummeted to $19.72 on December 29, 2025---a decline of approximately 42.32%---as the Company disclosed that both Phase III Orbit and Cosmic studies failed to achieve statistical significance against their primary endpoints of reduced annualized fracture rates.
Alleged Stock Drop Impact by the Numbers
Start your claim now or call (212) 363-7500.
What the Corrective Disclosure Revealed
It is alleged that the December 29, 2025 disclosure revealed critical information previously concealed from investors: while setrusumab achieved bone mineral density improvements, these "were not accompanied by a corresponding reduction in annualized fracture rates." The Company attributed the failure to a "low fracture rate in the placebo group" in Orbit and a trend that "did not meet statistical significance" in Cosmic.
"The complaint raises serious questions about whether investors received accurate information about clinical trial risks and variability challenges," said Joseph E. Levi, Esq. "Our team is thoroughly investigating these claims on behalf of affected shareholders."
Levi & Korsinsky, LLP --- Top 50 securities litigation firm (ISS Securities Class Action Services, seven consecutive years). Over 70 professionals. Hundreds of millions recovered for investors nationwide.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
(212) 363-7500
jlevi@levikorsinsky.com
www.zlk.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/levi--korsinsky-llp-rare-stock-declined-over-42-following-phase-iii-study-failure-disclosure-302703560.html
SOURCE Levi & Korsinsky, LLP
Hinweis: ARIVA.DE veröffentlicht in dieser Rubrik Analysen, Kolumnen und Nachrichten aus verschiedenen Quellen. Die ARIVA.DE AG ist nicht verantwortlich für Inhalte, die erkennbar von Dritten in den „News“-Bereich dieser Webseite eingestellt worden sind, und macht sich diese nicht zu Eigen. Diese Inhalte sind insbesondere durch eine entsprechende „von“-Kennzeichnung unterhalb der Artikelüberschrift und/oder durch den Link „Um den vollständigen Artikel zu lesen, klicken Sie bitte hier.“ erkennbar; verantwortlich für diese Inhalte ist allein der genannte Dritte.
